The Oncology Brothers are joined by Virginia Kaklamani, MD, DSc, who provides an overview of the EMERALD trial design and use of elacestrant in ER+, HER2- advanced breast cancer.
Key Takeaways From EMERALD: Elacestrant in Patients With Previously Treated ER+, HER2- Metastatic Breast Cancer
EP. 2: EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer: Efficacy and Safety Data
By
Expert oncologist Virginia Kaklamani, MD, DSc, joins the Oncology Brothers in highlighting the efficacy and safety data from the EMERALD trial and identifying appropriate use of elacestrant in patients with ER+, HER2- advanced breast cancer.
Following their discussion of the EMERALD trial and elacestrant with Virginia Kaklamani, MD, DSc, the Oncology Brothers share clinical implications of the EMERALD trial to practice and look toward the future of ER+, HER2- advanced breast cancer management.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
3
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
4
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
5
